Scholarlink

<p><i>NUP98</i> fusions are molecularly rare in T-cell acute lymphoblastic leukemia (T-ALL), with limited data available regarding treatment response and clinical outcomes. Here, we report a case of T-ALL harboring a <i>NUP98::ADD3</i> fusion (involving <i>NUP98</i> exon 13 and <i>ADD3</i> exon 13), representing only the second documented instance of this genetic rearrangement in T-ALL. Notably, the patient demonstrated refractoriness to venetoclax-based chemotherapy. To our knowledge, this is the first report of a T-ALL case with the <i>NUP98::ADD3</i> fusion exhibiting resistance to venetoclax-containing regimens.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Venetoclax-based chemotherapy failure in adult T-cell acute lymphoblastic leukemia with NUP98::ADD3 fusion: a case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月31日

查看全文
  • Ting Shi,
  • Zhanrui Cheng,
  • Zhiyao Zhang,
  • Xingran Jiang,
  • Yantian Zhao,
  • Yin Wu,
  • Hong-hu Zhu

摘要

NUP98 fusions are molecularly rare in T-cell acute lymphoblastic leukemia (T-ALL), with limited data available regarding treatment response and clinical outcomes. Here, we report a case of T-ALL harboring a NUP98::ADD3 fusion (involving NUP98 exon 13 and ADD3 exon 13), representing only the second documented instance of this genetic rearrangement in T-ALL. Notably, the patient demonstrated refractoriness to venetoclax-based chemotherapy. To our knowledge, this is the first report of a T-ALL case with the NUP98::ADD3 fusion exhibiting resistance to venetoclax-containing regimens.